Compare Neurocrine Biosciences Inc (NBIX) vs iShares 10 20 Year Treasury Bond ETF (TLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs iShares 10 20 Year Treasury Bond ETF — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while iShares 10 20 Year Treasury Bond ETF trades at $97.83. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, iShares 10 20 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | TLH | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Fixed Income |
52-Week High | $180.55 | $105.36 |
52-Week Low | $123.10 | $97.13 |
Enterprise Value | $16.49B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About iShares 10 20 Year Treasury Bond ETF
TLH tracks the ICE U.S. Treasury 10-20 Year Bond Index, offering targeted exposure to intermediate-to-long term government debt. It serves as a middle ground between the 7-10 year (IEF) and 20+ year (TLT) ETFs, balancing yield and duration risk.
Read more on TLH →
